Lunsumio is a Intravenous Concentrate in the Human Prescription Drug category. It is labeled and distributed by Genentech, Inc.. The primary component is Mosunetuzumab.
Product ID | 50242-159_3c8d2a27-5057-4c5a-b9fc-c6d67afdd2f7 |
NDC | 50242-159 |
Product Type | Human Prescription Drug |
Proprietary Name | Lunsumio |
Generic Name | Mosunetuzumab |
Dosage Form | Concentrate |
Route of Administration | INTRAVENOUS |
Marketing Start Date | 2022-12-22 |
Marketing Category | BLA / |
Application Number | BLA761263 |
Labeler Name | Genentech, Inc. |
Substance Name | MOSUNETUZUMAB |
Active Ingredient Strength | 1 mg/mL |
NDC Exclude Flag | N |
Listing Certified Through | 2023-12-31 |
Marketing Start Date | 2022-12-22 |
NDC Exclude Flag | N |
Sample Package? | N |
NDC | Brand Name | Generic Name |
---|---|---|
50242-142 | Lunsumio | Mosunetuzumab |
50242-159 | Lunsumio | Mosunetuzumab |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
LUNSUMIO 97347318 not registered Live/Pending |
Genentech, Inc. 2022-04-05 |
LUNSUMIO 90706107 not registered Live/Pending |
Genentech, Inc. 2021-05-12 |